Pazopanib restricts small cell lung cancer proliferation via reactive oxygen species‐mediated endoplasmic reticulum stress

BACKGROUND: Pazopanib is an approved multitarget anticancer agent for soft tissue sarcoma (STS) and renal cell carcinoma (RCC), which is also under clinical investigation for other malignancies, including small cell lung cancer (SCLC). However, the potential anti‐SCLC mechanisms of pazopanib remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yue, Chen, Chen, Liu, Hai‐Lin, Li, Chen‐Guang, Zhang, Zhen‐Fa, Wang, Chang‐Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436657/
https://www.ncbi.nlm.nih.gov/pubmed/35866204
http://dx.doi.org/10.1111/1759-7714.14543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436657/
https://www.ncbi.nlm.nih.gov/pubmed/35866204
http://dx.doi.org/10.1111/1759-7714.14543

Ejemplares similares